Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days.

Trial Profile

A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Ciprofloxacin; Finafloxacin
  • Indications Bacterial infections; Urinary tract infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FLUT
  • Most Recent Events

    • 16 Jan 2018 Results of pooled data from two trials (NCT01928433 and NCT00722735) assessing the clinical efficacy and antibacterial activity of finafloxacin compared with ciprofloxacin in the treatment of uUTI and cUTI/PN, were published in the Antimicrobial Agents and Chemotherapy.
    • 21 Sep 2015 Pooled analysis results from this trial and an another trial presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 30 Apr 2012 Planned number of patients changed from 36 to 48 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top